Skip to ContentSkip to Navigation
Research Pediatrics
University Medical Center Groningen

New Key Publication:Personalised modelling of clinical heterogeneity between medium-chain acyl-CoA dehydrogenase patients

04 September 2023

Background: Monogenetic inborn errors of metabolism cause a wide phenotypic heterogeneity that may even differ between family members carrying the same genetic variant. Computational modelling of metabolic networks may identify putative sources of this inter-patient heterogeneity. Here, we mainly focus on medium-chain acyl-CoA dehydrogenase deficiency (MCADD), the most common inborn error of the mitochondrial fatty acid oxidation (mFAO). It is an enigma why some MCADD patients-if untreated-are at risk to develop severe metabolic decompensations, whereas others remain asymptomatic throughout life. We hypothesised that an ability to maintain an increased free mitochondrial CoA (CoASH) and pathway flux might distinguish asymptomatic from symptomatic patients.

Results: We built and experimentally validated, for the first time, a kinetic model of the human liver mFAO. Metabolites were partitioned according to their water solubility between the bulk aqueous matrix and the inner membrane. Enzymes are also either membrane-bound or in the matrix. This metabolite partitioning is a novel model attribute and improved predictions. MCADD substantially reduced pathway flux and CoASH, the latter due to the sequestration of CoA as medium-chain acyl-CoA esters. Analysis of urine from MCADD patients obtained during a metabolic decompensation showed an accumulation of medium- and short-chain acylcarnitines, just like the acyl-CoA pool in the MCADD model. The model suggested some rescues that increased flux and CoASH, notably increasing short-chain acyl-CoA dehydrogenase (SCAD) levels. Proteome analysis of MCADD patient-derived fibroblasts indeed revealed elevated levels of SCAD in a patient with a clinically asymptomatic state. This is a rescue for MCADD that has not been explored before. Personalised models based on these proteomics data confirmed an increased pathway flux and CoASH in the model of an asymptomatic patient compared to those of symptomatic MCADD patients.

Conclusions: We present a detailed, validated kinetic model of mFAO in human liver, with solubility-dependent metabolite partitioning. Personalised modelling of individual patients provides a novel explanation for phenotypic heterogeneity among MCADD patients. Further development of personalised metabolic models is a promising direction to improve individualised risk assessment, management and monitoring for inborn errors of metabolism.

Authors:

  • Christoff Odendaal
  • Emmalie A Jager
  • Anne-Claire M F Martines
  • Marcel A Vieira-Lara
  • Nicolette C A Huijkman
  • Ligia A Kiyuna
  • Albert Gerding
  • Justina C Wolters
  • Rebecca Heiner-Fokkema
  • Karen van Eunen
  • Terry G J Derks
  • Barbara M Bakker

Read more BMC :https://bmcbiol.biomedcentral.com/articles/10.1186/s12915-023-01652-9

Last modified:11 September 2023 09.37 a.m.

More news

  • 12 September 2023

    Art in times of AI

    Leonardo Arriagada Beltran conducted his PhD research on the interface of computer-generated art and the constantly evolving field of Artificial Intelligence (AI). He will defend his Phd thesis on 21 September. His research offers valuable insights...

  • 28 August 2023

    Harish Vedantham and Casper van der Kooi nominated for 'Wetenschapstalent 2023'

    Harish Vedantham and Casper van der Kooi have been nominated by New Scientist for Wetenschapstalent 2023 (Science Talent 2023). This election is meant to give young scientists and their research a stage.

  • 26 July 2023

    Five promising UG researchers to top institutes abroad on Rubicon grants

    No less than five promising PhD graduates from the University of Groningen will be able to conduct research at top institutes abroad for two years thanks to the Rubicon programme organized by the Netherlands Organisation for Scientific Research...